Immunic (NASDAQ:IMUX) Receives Consensus Rating of “Strong Buy” from Analysts

Shares of Immunic (NASDAQ:IMUX) have received a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy recommendation.

Brokerages have set a 1 year consensus price target of $45.00 for the company, according to Zacks. Zacks has also assigned Immunic an industry rank of 51 out of 256 based on the ratings given to its competitors.

Separately, Chardan Capital initiated coverage on shares of Immunic in a research note on Thursday, July 11th. They issued a “buy” rating and a $40.00 target price for the company.

NASDAQ IMUX traded down $0.48 during trading on Friday, reaching $13.10. The company’s stock had a trading volume of 42,564 shares, compared to its average volume of 176,969. The stock has a market capitalization of $13.87 million, a PE ratio of -0.37 and a beta of 3.69. Immunic has a 1-year low of $6.00 and a 1-year high of $390.00.

About Immunic

Immunic, Inc, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis.

Read More: What does an outperform rating mean?

Get a free copy of the Zacks research report on Immunic (IMUX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.